Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13598112 | 0.82 | DHFR (0.57) | DHFRNOS1 | |
| SCHEMBL4814896 | 0.78 | DHFR (0.70) | DHFR | |
| SCHEMBL4685928 | 0.74 | DHFR (0.61) | DHFR | |
| SCHEMBL28524722 | 0.74 | NOS1 (0.54) | DHFRNOS1 | |
| SCHEMBL8813993 | 0.74 | NOS1 (0.61) | DHFRNOS1 | |
| SCHEMBL14252994 | 0.73 | DHFR (0.49) | DHFRNOS1 | |
| SCHEMBL5861648 | 0.73 | DHFR (0.57) | DHFR | |
| SCHEMBL14100003 | 0.73 | DHFR (0.62) | DHFR | |
| SCHEMBL9621108 | 0.72 | DHFR (0.51) | DHFRNOS1 | |
| SCHEMBL30432658 | 0.72 | NOS1 (0.55) | DHFRNOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882862-B2 | Compositions, methods, and kits for quantifying methotrexate | MICROMASS UK LIMITED (GB) | 2021-01-05 | — | — | US | disclosed |
| US-20200216453-A1 | COMPOSITIONS, METHODS, AND KITS FOR QUANTIFYING METHOTREXATE | MICROMASS UK LIMITED (GB) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882862-B2 | Compositions, methods, and kits for quantifying methotrexate | MTX1, MTX2, MTHFD2 | DHFR 4/4885NOS1 4211/4885 |
| US-20200216453-A1 | COMPOSITIONS, METHODS, AND KITS FOR QUANTIFYING METHOTREXATE | MTX1, MTX2, MTHFD1 | DHFR 8/4885NOS1 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.